دورية أكاديمية
Respiratory virus circulation during the first year of the COVID-19 pandemic in the Household Influenza Vaccine Evaluation (HIVE) cohort.
العنوان: | Respiratory virus circulation during the first year of the COVID-19 pandemic in the Household Influenza Vaccine Evaluation (HIVE) cohort. |
---|---|
المؤلفون: | Fine SR; Department of Epidemiology University of Michigan Ann Arbor Michigan USA., Bazzi LA; Department of Epidemiology University of Michigan Ann Arbor Michigan USA.; Present address: Northwestern University Evanston Illinois USA.; Present address: Northwestern University Evanston Illinois USA., Callear AP; Department of Epidemiology University of Michigan Ann Arbor Michigan USA., Petrie JG; Department of Epidemiology University of Michigan Ann Arbor Michigan USA.; Present address: Marshfield Clinic Research Institute Marshfield Wisconsin USA.; Present address: Marshfield Clinic Research Institute Marshfield Wisconsin USA., Malosh RE; Department of Epidemiology University of Michigan Ann Arbor Michigan USA.; Present address: Michigan Department of Health and Human Services Lansing Michigan USA.; Present address: Michigan Department of Health and Human Services Lansing Michigan USA., Foster-Tucker JE; Department of Epidemiology University of Michigan Ann Arbor Michigan USA., Smith M; Department of Epidemiology University of Michigan Ann Arbor Michigan USA., Ibiebele J; Department of Epidemiology University of Michigan Ann Arbor Michigan USA., McDermott A; Vaccine Research Center National Institute of Allergy and Infectious Diseases, National Institutes of Health Bethesda Maryland USA., Rolfes MA; Influenza Division Centers for Disease Control and Prevention Atlanta Georgia USA., Monto AS; Department of Epidemiology University of Michigan Ann Arbor Michigan USA., Martin ET; Department of Epidemiology University of Michigan Ann Arbor Michigan USA. |
المصدر: | Influenza and other respiratory viruses [Influenza Other Respir Viruses] 2023 Mar 01; Vol. 17 (3), pp. e13106. Date of Electronic Publication: 2023 Mar 01 (Print Publication: 2023). |
نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S. |
اللغة: | English |
بيانات الدورية: | Publisher: Wiley Country of Publication: England NLM ID: 101304007 Publication Model: eCollection Cited Medium: Internet ISSN: 1750-2659 (Electronic) Linking ISSN: 17502640 NLM ISO Abbreviation: Influenza Other Respir Viruses Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: Oxford, UK : Wiley, c2007- |
مواضيع طبية MeSH: | Influenza Vaccines* , Influenza, Human* , COVID-19*, Humans ; Pandemics ; SARS-CoV-2 ; Rhinovirus |
مستخلص: | Background: The annual reappearance of respiratory viruses has been recognized for decades. COVID-19 mitigation measures taken during the pandemic were targeted at respiratory transmission and broadly impacted the burden of acute respiratory illnesses (ARIs). Methods: We used the longitudinal Household Influenza Vaccine Evaluation (HIVE) cohort in southeast Michigan to characterize the circulation of respiratory viruses from March 1, 2020, to June 30, 2021, using RT-PCR of respiratory specimens collected at illness onset. Participants were surveyed twice during the study period, and SARS-CoV-2 antibodies were measured in serum by electrochemiluminescence immunoassay. Incidence rates of ARI reports and virus detections were compared between the study period and a preceding pre-pandemic period of similar duration. Results: Overall, 437 participants reported a total of 772 ARIs; 42.6% had respiratory viruses detected. Rhinoviruses were the most frequent virus, but seasonal coronaviruses, excluding SARS-CoV-2, were also common. Illness reports and percent positivity were lowest from May to August 2020, when mitigation measures were most stringent. Seropositivity for SARS-CoV-2 was 5.3% in summer 2020 and increased to 11.3% in spring 2021. The incidence rate of total reported ARIs for the study period was 50% lower (95% CI: 0.5, 0.6; p < 0.001) than the incidence rate from a pre-pandemic comparison period (March 1, 2016, to June 30, 2017). Conclusions: The burden of ARI in the HIVE cohort during the COVID-19 pandemic fluctuated, with declines occurring concurrently with the widespread use of public health measures. Rhinovirus and seasonal coronaviruses continued to circulate even when influenza and SARS-CoV-2 circulation was low. Competing Interests: ETM reports grant funding from Merck outside of the submitted work. (© 2023 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.) |
التعليقات: | Update of: medRxiv. 2022 Dec 09;:. (PMID: 36523413) |
References: | PLoS One. 2009 Aug 24;4(8):e6671. (PMID: 19701458) Int J Epidemiol. 2019 Aug 1;48(4):1040-1040g. (PMID: 31038700) J Clin Microbiol. 1997 Nov;35(11):2864-8. (PMID: 9350748) J Virol Methods. 2020 Sep;283:113919. (PMID: 32554043) Paediatr Respir Rev. 2003 Jun;4(2):105-11. (PMID: 12758047) PLoS Comput Biol. 2010 Jan 29;6(1):e1000656. (PMID: 20126529) Am J Public Health. 1982 Nov;72(11):1280-3. (PMID: 7125031) J Infect Dis. 2021 Jul 2;224(1):49-59. (PMID: 33755731) Nature. 2006 Jul 27;442(7101):448-52. (PMID: 16642006) Clin Infect Dis. 2021 Oct 5;73(7):1248-1256. (PMID: 33949666) Clin Infect Dis. 2021 Dec 6;73(11):e4384-e4391. (PMID: 33095882) Influenza Other Respir Viruses. 2021 Mar;15(2):227-234. (PMID: 33107200) Proc Natl Acad Sci U S A. 2020 Dec 1;117(48):30547-30553. (PMID: 33168723) BMC Public Health. 2021 Jun 21;21(1):1178. (PMID: 34154549) Environ Res. 2021 Mar;194:110716. (PMID: 33421429) Pediatr Infect Dis J. 2004 Jan;23(1 Suppl):S58-64. (PMID: 14730271) Nat Commun. 2022 May 24;13(1):2884. (PMID: 35610217) J Infect Dis. 2014 Dec 1;210(11):1792-9. (PMID: 24907381) Pediatrics. 2021 Aug;148(2):. (PMID: 33986150) Nat Rev Dis Primers. 2018 Jun 28;4(1):3. (PMID: 29955068) Influenza Other Respir Viruses. 2022 May;16(3):521-531. (PMID: 34821476) J Clin Microbiol. 2021 Jun 18;59(7):e0043121. (PMID: 33903168) Influenza Other Respir Viruses. 2021 Nov;15(6):804-812. (PMID: 34219389) Emerg Infect Dis. 2021 Feb;27(2):641-643. (PMID: 33263515) J Infect Dis. 2007 Mar 15;195(6):765-6. (PMID: 17299703) PLoS Pathog. 2018 Feb 15;14(2):e1006770. (PMID: 29447284) BMC Med. 2021 Feb 5;19(1):40. (PMID: 33541353) Pediatr Infect Dis J. 2020 Dec;39(12):e423-e427. (PMID: 32773660) J Infect Dis. 2018 Jul 2;218(3):406-417. (PMID: 29746640) Am J Respir Crit Care Med. 2012 Jun 15;185(12):1275-9. (PMID: 22366048) J Pediatr. 2021 Jul;234:164-171.e2. (PMID: 33774057) J Antimicrob Chemother. 1999 Nov;44 Suppl B:3-9. (PMID: 10877456) Proc Natl Acad Sci U S A. 2019 Dec 26;116(52):27142-27150. (PMID: 31843887) |
معلومات مُعتمدة: | 75N93021C00015 United States AI NIAID NIH HHS; U01 IP001034 United States IP NCIRD CDC HHS; U01IP001034 United States ACL ACL HHS |
فهرسة مساهمة: | Keywords: COVID‐19; household cohort; influenza; respiratory virus; serological surveillance |
المشرفين على المادة: | 0 (Influenza Vaccines) |
تواريخ الأحداث: | Date Created: 20230306 Date Completed: 20230307 Latest Revision: 20240503 |
رمز التحديث: | 20240503 |
مُعرف محوري في PubMed: | PMC9975790 |
DOI: | 10.1111/irv.13106 |
PMID: | 36875204 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1750-2659 |
---|---|
DOI: | 10.1111/irv.13106 |